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Abstract
Objective To describe adult-onset limb-girdle-type muscular dystrophy caused by biallelic variants in the PYROXD1 gene, 
which has been recently linked to early-onset congenital myofibrillar myopathy.
Methods Whole exome sequencing was performed for adult-onset neuromuscular disease patients with no molecular diag-
nosis. Patients with PYROXD1 variants underwent clinical characterization, lower limb muscle MRI, muscle biopsy and 
spirometry. A yeast complementation assay was used to determine the biochemical consequences of the genetic variants.
Results We identified four patients with biallelic PYROXD1 variants. Three patients, who had symptom onset in their 20s 
or 30s, were homozygous for the previously described p.Asn155Ser. The fourth patient, with symptom onset at age 49, 
was compound heterozygous for p.Asn155Ser variant and previously unknown p.Tyr354Cys. All patients presented with a 
LGMD-type phenotype of symmetric muscle weakness and wasting. Symptoms started in proximal muscles of the lower 
limbs, and progressed slowly to involve also upper limbs in a proximal-predominant fashion. All patients remained ambulant 
past the age of 60. They had restrictive lung disease but no cardiac impairment. Muscle MRI showed strong involvement of 
anterolateral thigh muscles. Muscle biopsy displayed chronic myopathic changes. Yeast complementation assay demonstrated 
the p.Tyr354Cys mutation to impair PYROXD1 oxidoreductase ability.
Conclusion PYROXD1 variants can cause an adult-onset slowly progressive LGMD-type phenotype.
Keywords Limb-girdle muscular dystrophy · PYROXD1 · Myopathy · Exome sequencing
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Introduction
Inherited disorders of the skeletal muscles are classified 
based on clinical, histopathological and genetic features. 
Limb-girdle muscular dystrophy (LGMD) is a genetically 
heterogeneous group of muscular dystrophies with auto-
somal inheritance characterized by slowly progressive 
degeneration of proximal limb muscles. In many types of 
LGMD also other muscles, e.g., distal muscles, respiratory 
muscle and the heart may be affected. Inheritance can be 
either dominant (LGMD1) or recessive (LGMD2), and to 
date at least 34 LGMD disease genes are known [1–3]. 
Distribution of muscle involvement, age at onset and rate 
of progression show great variability, which are under-
scored by the extensive genetic diversity.
Biallelic PYROXD1 gene mutations were identified to 
underlie congenital myopathy in nine patients from five 
different families [4]. These patients had the onset of mus-
cle weakness between birth and 8 years with slow dis-
ease progression, and muscle pathology consistent with 
myofibrillar myopathy. All patients were still ambulant 
at the time of study, the oldest patient being 31 years of 
age. PYROXD1 encodes a nuclear-cytoplasmic oxidore-
ductase, with a currently unknown exact function in cel-
lular redox regulation [4]. Patients from four families had 
a mutation causing p.Asn155Ser amino acid change, which 
was shown to impair reductase activity in a complemen-
tation assay of yeast lacking glutathione reductase [4]. 
Another patient with homozygous p.Asn155Ser variant 
was recently reported, presenting with progressive muscle 
weakness starting at the age of 9 years and leading to loss 
of ambulation at the age of 37 years [5].
Here we describe additional four patients from three 
families with recessive PYROXD1 variants. In contrast to 
the previous report, our patients had the disease onset in 
adulthood and have now reached 60 years of age, allowing 
evaluation of the natural history of PYROXD1 associated 
disease.
Materials and methods
Patients
The patients in this study are from three families of Finn-
ish origin with non-consanguineous parents (Fig.1). 
Patients; patient 1 (P1, Family 1), patient 2 (P2, Family 2), 
and siblings patient 3 and 4 (P3 and P4, Family 3), were 
studied in cohorts of undiagnosed neuromuscular disease 
patients. In addition to detailed clinical neurological exam-
inations, all patients underwent electroneuromyography 
(ENMG) investigations, muscle biopsy, lower limb muscle 
MRI, spirometry/respiratory assessment and measurement 
of serum creatine kinase (CK) values (Table1). The MR 
images of patient P4 had been performed a long time ago 
at age 45 years and therefore only the written radiology 
report was available for review. Whole-body MRI had 
been performed in two patients (P1 and P2).
Muscle biopsies were histochemically stained with hae-
matoxylin & eosin (H&E), Gomöri trichrome, nicotinamide 
adenine dinucleotide tetrazolium reductase (NADH-TR) and 
combined cytochrome oxidase (COX)/succinate dehydro-
genase (SDH). The following immunohistochemical stain-
ings were performed for P1 and P3: MyHC double staining 
[Myosin Heavy Chain, Slow, Myosin Heavy Chain, A4.74 
(fast)], p62, myotilin and desmin. Furthermore, biopsies 
from P1 and P2 were stained for sarcolemmal proteins dys-
trophin 1–3, dysferlin, sarcoglycan-alpha, dystroglycan-
alpha and caveolin-3 in addition to merosin and emerin. For 
P2, only archival histological and histochemical stainings 
were available, and thus MyHC, p62, myotilin or desmin 
immunohistochemical stainings were not possible.
All subjects in this study have provided written consent 
for the use of clinical data and material. The study was 
approved by Helsinki University Hospital and Tampere 
University Hospital ethics boards.
DNA sequencing
For P1 and P2, whole exome sequencing (WES) was per-
formed at the Finnish Institute of Molecular Medicine 
(FIMM). Briefly, 150ng of gDNA was fragmented with a 
Covaris E220 evolution instrument (Covaris). Sample librar-
ies were processed according to SeqCapEZ Library SR 
(Roche Nimblegen) manual. NimbleGen capture was per-
formed according to NimbleGen SeqCap EZ Exome Library 
SR User’s Guide. Sequencing was performed with Illumina 
HiSeq2500 system in Rapid mode using HiSeq Rapid v2 kits 
(Illumina). Reads were then aligned to the GRCh37 refer-
ence genome with the BWA (0.6.2), and the mpileup from 
the SAMTOOLS (1.4) package was used for variant calling.
Fig. 1  Family pedigrees and the identified PYROXD1 variants
355Journal of Neurology (2019) 266:353–360 
1 3
Ta
bl
e 
1 
 C
lin
ica
l f
ea
tu
re
s o
f t
he
 pa
tie
nt
s
FV
C
 fo
rc
ed
 vi
tal
 ca
pa
cit
y, 
M
IP
 m
ax
im
um
 in
sp
ira
to
ry
 pr
es
su
re
, M
EP
 m
ax
im
um
 ex
pi
ra
to
ry
 pr
es
su
re
, P
C
F 
pe
ak
 co
ug
h fl
ow
a  A
ge
 at
 de
ath
 du
e t
o r
es
pi
ra
to
ry
 in
su
ffi
cie
nc
y a
nd
 pn
eu
m
on
ia
Fa
m
ily
1
2
3
3
Pa
tie
nt
P1
P2
P3
P4
Ge
nd
er,
 ag
e
M
ale
, 6
5 y
ea
rs
M
ale
, 6
5 y
ea
rs
M
ale
, 7
0 y
ea
rs
Fe
m
ale
, 7
0 y
ea
rsa
Et
hn
ici
ty,
 co
ns
an
gu
in
ity
Fi
nn
ish
, n
o
Fi
nn
ish
, n
o
Fi
nn
ish
, n
o
Fi
nn
ish
, n
o
PY
RO
XD
1 v
ar
ian
ts
c.4
64
A 
> 
G 
(p
.A
sn
15
5S
er,
 ch
r1
2:
 
g.2
16
05
06
4A
 >
 G
), 
c.1
06
1A
 >
 G
 
(p
. T
yr
35
4C
ys
, c
hr
12
:g
. 1
2:
 
21
61
57
41
A 
> 
G)
Ho
m
, c
.46
4A
 >
 G
 (p
.A
sn
15
5S
er,
 
ch
r1
2:
 g.
21
60
50
64
A 
> 
G)
Ho
m
, c
.46
4A
 >
 G
 (p
.A
sn
15
5S
er,
 
ch
r1
2:
 g.
21
60
50
64
A 
> 
G)
Ho
m
, c
.46
4A
 >
 G
 (p
.A
sn
15
5S
er,
 
ch
r1
2:
 g.
21
60
50
64
A 
> 
G)
On
se
t/p
ro
gr
es
sio
n
49
 ye
ar
s, 
slo
wl
y p
ro
gr
es
siv
e
10
 ye
ar
s, 
slo
wl
y p
ro
gr
es
siv
e
30
 ye
ar
s, 
slo
wl
y p
ro
gr
es
siv
e
33
 ye
ar
s, 
slo
wl
y p
ro
gr
es
siv
e
Ag
e o
n l
as
t c
om
pr
eh
en
siv
e e
xa
m
in
a-
tio
n, 
se
ve
rit
y
63
 ye
ar
s, 
am
bu
lan
t w
ith
ou
t a
id
s, 
he
lp
 fr
om
 bo
th
 ha
nd
s w
he
n r
isi
ng
 
fro
m
 ch
air
64
 ye
ar
s, 
am
bu
lan
t w
ith
 tw
o s
tic
ks
, 
ky
ph
ot
ic 
po
stu
re
 an
d a
tro
ph
ic 
up
pe
r b
ac
k m
us
cle
s
70
 ye
ar
s, 
am
bu
lan
t w
ith
 1–
2 s
tic
ks
 
fo
r 2
00
 m
, s
ev
er
e p
ro
xi
m
al 
up
pe
r 
an
d l
ow
er
 li
m
b w
ea
kn
es
s
70
 ye
ar
s, 
wh
ee
lch
air
 bo
un
d (
66
 ye
ar
s)
Re
str
ict
ive
 lu
ng
 di
se
as
e
Ye
s, 
FV
C 
54
% 
(6
3 y
ea
rs)
Ye
s, 
ep
iso
di
c d
ys
pn
ea
 an
d F
VC
 40
% 
(6
4 y
ea
rs)
Ye
s, 
FV
C 
67
% 
wi
th
 se
ve
re
ly
 
re
du
ce
d M
IP
, M
EP
 an
d P
CF
 va
l-
ue
s (
70
 ye
ar
s)
Ye
s, 
FV
C 
42
% 
(5
9 y
ea
rs)
 an
d 3
0%
 
(6
8 y
ea
rs)
Di
sta
l a
nd
 pr
ox
im
al 
up
pe
r l
im
b 
str
en
gt
hs
Pr
ox
. 4
/5
Di
st.
 5/
5
Pr
ox
. 2
/5
Di
st.
 4/
5
Pr
ox
. 3
/5
, 2
/5
Di
st.
 4/
5
Pr
ox
. 4
/5
, 2
/5
Di
st.
 3.
5/
5
Hi
p fl
ex
io
n s
tre
ng
th
3/
5
2/
5
1/
5
2/
5
Kn
ee
 fl
ex
io
n/
ex
ten
sio
n
Fl
ex
. 4
/5
Ex
t. 
4/
5
Fl
ex
. 3
/5
Ex
t. 
2/
5
Fl
ex
. 3
/5
Ex
t. 
2/
5
Ex
t. 
2/
5
Di
sta
l l
ow
er
 li
m
b s
tre
ng
th
s
An
kl
e p
lan
tar
 an
d d
or
sa
l fl
ex
io
n 4
/5
 
(6
4 y
ea
rs)
An
kl
e d
or
sa
l fl
ex
io
n 3
/5
, p
lan
tar
 
fle
xi
on
 5/
5 (
65
 ye
ar
s)
An
kl
e p
lan
tar
 an
d d
or
sa
l fl
ex
io
n 3
/5
 
(7
0 y
ea
rs)
An
kl
e p
lan
tar
 an
d d
or
sa
l fl
ex
io
n 5
/5
 
(4
5 y
ea
rs)
Sp
in
al 
an
d t
ru
nc
al 
m
us
cle
s
M
od
er
ate
 vo
lu
m
e l
os
s
At
ro
ph
ic 
up
pe
r b
ac
k m
us
cle
s
Ne
ck
 fl
ex
or
, s
pi
na
l a
nd
 ab
do
m
in
al 
m
us
cle
 w
ea
kn
es
s
Ne
ck
 fl
ex
or
 an
d a
bd
om
in
al 
m
us
cle
 
we
ak
ne
ss
EM
G
Pr
ox
im
al 
an
d d
ist
al 
m
us
cle
 ab
no
rm
al 
m
ot
or
 un
it 
po
ten
tia
ls
M
yo
pa
th
ic 
ch
an
ge
s
M
yo
pa
th
ic 
ch
an
ge
s i
n p
ro
xi
m
al 
an
d 
pa
ra
sp
in
al 
m
us
cle
s
M
yo
pa
th
ic 
ch
an
ge
s i
n p
ro
xi
m
al 
m
us
cle
s
Ne
ur
og
ra
ph
y
No
rm
al
n.a
No
rm
al
No
rm
al
M
RI
Sy
m
m
etr
ic 
atr
op
hy
 an
d f
att
y r
ep
lac
e-
m
en
t i
n a
ll 
lo
we
r l
im
b m
us
cle
s, 
m
ild
 pr
ox
im
al 
atr
op
hy
 in
 up
pe
r 
lim
bs
 an
d s
ig
ni
fic
an
t a
tro
ph
y i
n 
m
us
cle
s o
f t
he
 pe
cto
ra
l g
ird
le
Sy
m
m
etr
ic 
atr
op
hy
 an
d f
at 
re
pl
ac
e-
m
en
t i
n a
ll 
m
us
cle
 co
m
pa
rtm
en
ts.
 
In
 th
e l
ow
er
 li
m
bs
, a
tro
ph
y w
as
 
fo
un
d r
ath
er
 un
ifo
rm
ly,
 w
he
re
as
 
in
 th
e u
pp
er
 li
m
bs
 it
 w
as
 re
lat
ive
ly
 
m
or
e a
dv
an
ce
d i
n d
or
sa
l c
om
pa
re
d 
to
 ve
nt
ra
l m
us
cle
s (
61
 ye
ar
s)
W
id
e s
pr
ea
d f
att
y r
ep
lac
em
en
t i
n 
gl
ut
ea
l, 
th
ig
h a
nd
 lo
we
r l
eg
 m
us
-
cle
s (
65
 ye
ar
s)
M
os
t s
ev
er
e f
att
y r
ep
lac
em
en
t i
n 
se
m
ite
nd
in
os
us
, s
ar
to
riu
s, 
gr
ac
ili
s. 
an
d g
as
tro
cn
em
iu
s m
ed
ial
is 
m
us
cle
s 
(4
5 y
ea
rs)
Bi
op
sy
Dy
str
op
hi
c
Dy
str
op
hi
c
Dy
str
op
hi
c
Dy
str
op
hi
c
CK
No
rm
al
28
8–
34
0 U
/l
No
rm
al
No
rm
al
Ac
yl
ca
rn
iti
ne
 pr
ofi
le
No
rm
al
n.a
n.a
n.a
Ca
rd
iac
 ul
tra
so
un
d
No
rm
al
No
rm
al 
(6
1 y
ea
rs)
No
rm
al 
(6
6 y
ea
rs)
n.a
356 Journal of Neurology (2019) 266:353–360
1 3
For family 3 (P3, P4 and their unaffected brother), WES 
was performed essentially by the same method, but library 
preparation was done using KAPA Hyper library preparation 
Kit (Kapa Biosystems, Wilmington, Ma, USA) and SeqCap 
EZ MedExome assay (Roche Nimblegen) was used for target 
enrichment.
Sanger sequencing was performed with primers spe-
cific for PYROXD1 exon 5 (CAG TGG GAA AGT GAG ATT 
CATTT and ATT ACG GAT TCC ACA AGA GCT) and exon 
10 (CCA TGG AAA TTC AGC TCA GGT and AAC AAC TGT 
GCT AGC TTC CT).
Plasmids, strains, media, and methods for yeast 
cells
The human PYROXD1 and PYROXD1-p.Tyr354Cys cDNAs 
were cloned by the Gateway® (Invitrogen) method into 
pDONR221 entry vector and then recombined into yeast 
destination vectors (Addgene;[6]) to obtain pAG415-
promGPD-PYROXD1 (pSF371) and pAG415-promGPD-
PYROXD1-p.Tyr354Cys (pSF501) plasmids. The pAG415 
is a low-copy number CEN plasmid bearing the constitu-
tive GPD (glyceraldehyde-3-phosphate dehydrogenase) pro-
moter and the LEU2 auxotrophic marker for selection of the 
transformants on SC-Leu medium. Plasmid sequences were 
verified (GATC Biotech). The Saccharomyces cerevisiae 
wild-type BY4742 (MATα leu2Δ0 ura3Δ0 his3Δ0 lys2Δ0) 
reference strain and the glr1∆ (MATα leu2Δ0 ura3Δ0 
his3Δ0 lys2Δ0 glr1::KanMX) mutant strain were used. Yeast 
cells were transformed using the modified lithium acetate 
method [7]. The indicated yeast strains were grown at 30°C 
to mid-exponential growth phase in synthetic complete (SC) 
medium SC-Leu: 0.67% yeast nitrogen base (YNB) without 
amino acids, 2% glucose and the appropriate—Leu drop-
out mix, to maintain the plasmid. These precultures were 
used to inoculate the rich medium YPD: 1% yeast extract, 
2% peptone, 2% glucose, or the oxidative stress medium 
YPD + H2O2: 1% yeast extract, 2% peptone, 2% glucose, 
3mM  H2O2, and the growth of the yeast cells was analysed 
at 30°C under agitation in liquid medium by measuring the 
OD at 600nm over time, with measurements every 10min 
over 17h.
For western blot analysis, total yeast protein extracts were 
prepared by NaOH lysis of 1.5  OD600nm unit of yeast cells, 
followed by trichloroacetic acid (TCA) precipitation and 
the pellet was resuspended in 50µl of 2X Laemmli buffer 
plus Tris Base. Samples were incubated 5 min at 37°C prior 
western-blot analysis by 8% SDS-PAGE, followed by trans-
fer on a nitrocellulose blotting membrane (Amersham™ 
Protran™ 0.45µm NC) and immunoblotting with rabbit 
polyclonal anti-PYROXD1 (1/500, R3500) antibodies [4] 
using standard procedures. Images were acquired with the 
ChemiDoc Touch Imaging System (Bio-Rad).
Results
Clinical features of P1
Patient 1 (Family 1) is a male who had been previously 
diagnosed with Ménière’s disease, but had been other-
wise healthy. He had slowly progressive proximal muscle 
weakness combined with back pain starting at the age of 
49 years (Table1). Before this his strengths had been nor-
mal, and he reported no problems with doing sports as a 
child or young adult. A lumbar disk herniation had been 
operated at the age of 51 years. At the age of 60 years, 
he was referred for neurologic consultation because of 
an incidental MRI finding of atrophy and fat replace-
ment symmetrically in the paravertebral lower back mus-
cles. The family history was negative for neuromuscular 
disease.
On clinical examination at the age of 63 years, he was 
ambulant without aids, but needed to use both hands when 
rising from a chair or climbing stairs. Moderate volume 
loss was noted in the upper paraspinal muscles, but oth-
erwise there was no evident atrophy. Distally upper limb 
strengths were normal, proximally slightly reduced on 
both sides. In the lower limbs, hip flexion and knee flex-
ion/extension strengths were decreased on both sides. Dis-
tal lower limb strengths were within normal limits. There 
was no facial or bulbar weakness.
Electromyography (EMG) of both proximal and distal 
muscles in all limbs showed abnormal motor unit poten-
tials (MUPs), either small polyphasic or large and partially 
polyphasic. Nerve conduction studies showed normal con-
duction velocities and sensory and motor amplitudes.
Plasma creatine kinase (CK), acylcarnitine profile and 
cardiac ultrasound were normal. Spirometry showed evi-
dence of moderate restrictive lung disease. High resolu-
tion CT of the thorax showed nodular parenchymal change 
consistent with pulmonary sarcoidosis. He was placed on 
an inhaled glucocorticoid.
Clinical features of P2
In his late teens before the age of 20 years, patient 2 (Fam-
ily 2) needed support from his hands to climb stairs and 
he had trouble running. Nevertheless, he played football 
at the age of 35 years, and started requiring walking aids 
only at the age of 54 years. On examination at the age of 
64 years he walked with two sticks, and short distances 
without aids. He had kyphotic posture and upper back 
muscles were noted as atrophic.
There was slight ptosis and facial weakness bilaterally. 
Limb strength was decreased predominantly proximally 
357Journal of Neurology (2019) 266:353–360 
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in a symmetric fashion. Arm elevation was less than 90° 
and elbow extension was severely decreased. Distal hand 
muscle strength was better preserved. In the lower limbs, 
hip flexion, knee extension and ankle dorsiflexion/plan-
tar flexion were severely affected, while knee flexion was 
moderately reduced.
EMG showed myopathic changes. Plasma CK was 
slightly increased. Cardiac ultrasound at age 61 years was 
normal. He had episodic dyspnea and reduced respiratory 
function (age 64 years), but so far has not required ventila-
tor support.
The patient’s brother had also been diagnosed with mus-
cle disease and died of pneumonia at the age of 43 years. 
Both parents and two older sisters were healthy.
Clinical features of patients P3 and P4
The proband P3 and his sister P4 (Family 3) were asymp-
tomatic until early thirties when they noticed weakness 
in their proximal lower limbs. They had difficulties rising 
from squat or chairs. Few years later muscle weakness 
was also reported in proximal upper limbs. The progres-
sion was very slow. At the age of 70 years the proband 
was ambulant with sticks for 200 m but rising from low 
chair was impossible. Gait was waddling with hyperex-
tended knees. He could elevate his arms less than 90°. 
His posture was normal although spinal and abdominal 
muscles were weak with mild neck flexor weakness. Also 
distal lower limb muscles were weak (ankle plantar and 
dorsal flexion grade 3). Scapular winging or facial weak-
ness was not observed. He had hoarseness in his voice but 
no other bulbar symptoms. He had had two strokes (left 
hemisphere aged 61 years and right hemisphere 66 years), 
which might contribute to the symptoms although acute 
hemiplegic symptoms had resolved. There was severe sym-
metrical muscle atrophy in the anterior part of the thigh, 
proximal upper limbs and shoulder girdle. He underwent 
echocardiography with normal results. Mild respiratory 
insufficiency and weak cough strength was observed in 
pulmonary function tests.
The sister, P4, started to use rollator at the age of 
65 years and wheelchair aged 66 years. She could not 
extend her knees and hip flexion was weak as well as neck 
flexors and abdominal muscles. She had asymmetrical 
upper limb weakness both proximally and distally with 
left side more severely affected. No bulbar symptoms were 
present. She had severe progressive respiratory insuffi-
ciency and she died from pneumonia aged 70 years. There 
were no cardiac symptoms; echocardiography was not per-
formed. Both siblings had normal CK levels. EMG showed 
myopathic changes especially in the proximal upper and 
lower limbs.
Muscle MRI and biopsy
Muscle MRI in all patients (P1, P2, P3 and P4) showed an 
unusual pattern of fatty dystrophic changes with total or 
near-total replacement of gluteus maximus, sartorius, gra-
cilis and quadriceps (Fig.2a–c). Similar to the original report 
on PYROXD1-related myopathy [4], rectus femoris was less 
affected than the vasti muscles. In the distal lower limbs, 
gastrocnemii were the most affected muscles in patients P2, 
Fig. 2  Muscle MRI and biopsies. MRI was performed for a indi-
vidual P1 at age 60, b individual P2 at age 59, and c individual P3 
at age 65. Gluteus maximus, quadriceps, sartorius and gracilis mus-
cles were most severely affected in all patients, although the most 
proximal parts of the rectus femoris muscles were relatively spared 
or even hypertrophic. Anterior thigh muscles were always more 
severely affected than the hamstrings and adductor compartments. A 
very peculiar pattern of fatty degeneration was observed in patients 
P2 and P3, where only the outer parts of the anterior and lateral com-
partment muscles were replaced by fat. In patient P1, there was an 
unusual crescent-shaped fatty-degeneration involving the inner parts 
of vastus lateralis and medialis muscles. Muscle biopsy (vastus lat-
eralis) from d individual P2 and e individual P1 showed a dystrophic 
pattern, where individual P2 had an almost end-stage pathology with 
severe atrophy, fibrosis and fatty infiltration. Scale bars 100µm
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P3 and P4, while all lower leg muscles were only mildly and 
diffusely affected in patient P1. In two patients (P2 and P3), 
a very peculiar pattern of fatty degeneration was observed, 
where the outer parts of the anterior and lateral compart-
ment muscles were replaced by fat, but not the inner portions 
(Fig.2b, c). No significant STIR edema was detected in any 
muscle, which is consistent with a relatively inactive and 
chronic degenerative process. Muscles of the upper girdle 
and the torso displayed diffuse fatty degenerative changes to 
a mild-moderate degree, while the muscles of the forearm 
and hand were minimally affected or entirely spared (not 
shown).
Muscle biopsies from the vastus lateralis of P2 (Fig.2d) 
and P1 (Fig.2e) showed chronic myopathic changes with 
atrophy, fat infiltration and strong fiber size variability, mul-
tiple internalized nuclei, and without significant myofibrillar 
pathology. Immunohistochemistry of sarcolemmal mem-
brane-associated proteins, merosin and emerin was normal. 
Stainings for p62, myotilin and desmin in P1 showed no 
myofibrillar features.
The first biopsies of the siblings, P3 and P4, were per-
formed 30 years ago and were not available for further analy-
sis. The morphological changes were reported to be dys-
trophic without specific features. Patient 3 underwent a new 
biopsy from tibialis anterior muscle at the age of 70. The 
muscle pathology showed extensive end-stage dystrophic 
changes. No fiber type predominance was noted. Immuno-
histochemical staining for myotilin revealed a few positive 
cytoplasmic inclusions in scattered atrophic muscle fibers 
(Supplementary Fig.1). However, no desmin- or p62-posi-
tive protein aggregates were found.
Genetic findings
The patients’ pedigrees suggested recessively inherited 
disease (Fig.1). Thus, the exome sequencing data were 
filtered for homozygous or compound heterozygous vari-
ants that induce damaging changes to amino acid sequence, 
have population frequency of less than 0.001 in the total 
population and Finnish sub-population in ExAC variant 
database, CADD-scores of 20 or greater, and are present 
in less than 1% of an in-house database with 429 samples 
(P1 and P2) or less than 4% of a separate in-house data-
base of 63 samples (P3 and P4). For P2, P3 and P4, the 
homozygous variant c.464A > G p.Asn155Ser in PYROXD1 
(ENST00000240651.9) caught our attention because of its 
recent association with myopathy [4]. In the previous study, 
this variant was identified in four out of five studied families 
as homozygous (two families) or compound heterozygous 
(two families), and it is present in variant databases as a low 
frequency European variant always in heterozygous state. 
According to the GnomAD database, its allele frequency 
is slightly higher in the Finnish population (1.186 × 10−4) 
than elsewhere. The unaffected brother in the family 3 was 
a heterozygous carrier of the p.Asn155Ser variant.
Patient 1 was compound heterozygous for the 
p.Asn155Ser and a previously unknown variant c.1061A > G 
p.Tyr354Cys. The latter variant is found in four heterozy-
gous individuals in the GnomAD database with a frequency 
of 1.444 × 10−5. The mutated tyrosine is located in the 
N-terminal end of the pyridine nucleotide oxidoreductase 
domain of PYROXD1 (Fig.3a), and the amino acid is evo-
lutionarily conserved (Fig.3b). Segregation of the variants 
was investigated in the family of patient 1, and the affected 
individual was the only one carrying both mutations. 
The p.Asn155Ser allele was inherited maternally and the 
p.Tyr354Cys paternally.
The PYROXD1‑p.Tyr354Cys is defective in oxidative 
stress resistance in yeast cells
Humanization of Saccharomyces cerevisiae yeast cells can 
be used to better understand and/or to identify the cellular 
role of a human protein [8, 9]. Indeed, the human PYROXD1 
cDNA was shown to rescue the oxidative stress defect asso-
ciated with the yeast glutathione oxidoreductase glr1∆ dele-
tion mutant strain [4]. Furthermore, the p.Asn155Ser vari-
ant was shown to have impaired rescue ability in the yeast 
complementation assay [4]. We tested here the effect of the 
new p.Tyr354Cys variant using the same yeast glr1∆ strain. 
The glr1∆ mutant cells were transformed by empty plasmid 
(pAG415) or by plasmids bearing either PYROXD1 wild-
type cDNA, or the mutant allele p.Tyr354Cys. Expression 
of the human cDNAs was controlled by western blot analysis 
with anti-PYROXD1 antibody, showing that the wild-type 
and the mutant form of PYROXD1 were expressed in two 
different clones (cl1 and cl2) of yeast cells (Fig.3c).
We observed that the yeast glutathione reductase glr1∆ 
mutant had a strong growth defect when grown in the pres-
ence of hydrogen peroxide (Fig.3d). As shown before, the 
expression of the human PYROXD1 cDNA was able to com-
plement the growth defect of the glr1∆ mutant cells [4], 
indicating that PYROXD1 has an oxidoreductase activity 
in vivo in yeast cells. Compared to wild-type PYROXD1, the 
p.Tyr354Cys variant had a lower growth rate in the presence 
of  H2O2, showing that this new patient mutation impairs the 
oxidoreductase activity of PYROXD1 in vivo in yeast cells 
(Fig.3d).
Discussion
We report here new patients with recessive PYROXD1 vari-
ants underlying myopathy phenotypes. In contrast to the 
congenital myopathy cases described previously [4, 5], our 
patients had a considerably later disease onset and lacked 
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significant myofibrillar pathology. In fact, a few myotilin-
positive inclusions were only observed in the end-stage 
degenerated muscle of one of our patients. The clinical pic-
ture of our patients was consistent with adult-onset, slowly 
progressive LGMD type disease. Reasons for the clear dif-
ference in disease onset between the patients of Turkish [4] 
and Sudanese of Arab [5] ancestry, and the Finnish patients 
of this study, who were homozygous for the p.Asn155Ser 
variant, are speculative at this point but may involve the pop-
ulation-specific genetic background or some environmental 
factors that are relevant for the regulation of PYROXD1 
oxidoreductase activity.
Muscle MRI may help to distinguish PYROXD1 myopa-
thy from other myopathies, as our patients showed an unu-
sual preference for anterolateral thigh muscles. Overall, the 
clinical course of the disease appears relatively benign, with 
preservation of ambulation past the age of 60. Respiratory 
impairment is a concern, however, as all our patients had 
developed respiratory muscle weakness and the brother of 
P2, who had been affected by a very similar kind of pro-
gressive muscle weakness, died from a respiratory infec-
tion at age 43 years. Also a 21-year-old patient described 
by O’Grady et al. had restrictive lung disease [4]. Regular 
monitoring of pulmonary function is therefore mandated in 
PYROXD1 myopathy. Fortunately, there appears to be no 
cardiac involvement.
It is important to note that the aged individuals in this 
study did not have evidence of neuropathy. While two 
affected individuals aged 26 and 29 years described by 
O’Grady et al. had an axonal neuropathy [4], our finding 
suggests that neuropathy is not a universal consequence of 
PYROXD1 variants even with advancing age. An important 
feature to note is axial myopathy, which was prominent in 
P1, and also present in 8/9 of O’Grady’s patients. It may 
be of interest to look for PYROXD1 variants in individuals 
presenting with pure axial myopathy, the genetics of which 
remains incompletely studied [10].
Three of our four patients were homozygous for the 
previously described p.Asn155Ser, whereas one was com-
pound heterozygous for the same variant and the previ-
ously undescribed p.Tyr354Cys. Both of these variants 
are found in different populations according to exome and 
genome databases, suggesting that additional patients will 
probably be identified. The p.Asn155Ser change appears 
to be a common pathogenic PYROXD1 variant, as most 
described patients carry it in one or both alleles. However, 
Fig. 3  PYROXD1 variants identified in this study and the functional 
characterization of p.Tyr354Cys in a yeast complementation assay. 
a A schematic of PYROXD1 with functional domains and the mis-
sense variants of patients of this study. b Evolutionary conservation 
of Tyr354. c Western blot of glr1Δ yeast cells transformed with yeast 
expression vectors empty (pAG415) or bearing the PYROXD1 wild-
type (WT) or p.Tyr354Cys (Y354C) under the control of a constitu-
tive promoter, two different clones (cl1 and cl2) were analyzed. The 
black arrows indicate the PYROXD1 protein and the loading con-
trol. d The indicated yeast cells were grown at 30 °C in rich medium 
(YPD) containing  H2O2 (3  mM) to induce an oxidative stress. The 
growth curves of the different strains were determined by measuring 
the cell growth (OD at 600 nm) over time (h)
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the associated myopathy can have highly variable ages of 
onset. Our patient, P1, who was compound heterozygous 
for the p.Tyr354Cys variant together with p.Asn155Ser 
had the highest age of onset of all patients, suggesting that 
p.Tyr354Cys might impair the function of PYROXD1 less 
than the p.Asn155Ser variant.
In conclusion, our study shows that PYROXD1 should be 
considered as a causative gene also in later-onset unsolved 
myopathies, which resemble LGMD.
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